FDA Action Against Three Drug Firms For Violations

PUNE:  The Food and Drug Administration (FDA), Pune division, has acted against three drug stores for violation of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

The action was taken between April and October 2024 by the FDA, Pune division said the officials in the statement.

According to officials as per the DMR Act, advertisements for drugs for 54 diseases and disorders that fall under the schedule are prohibited. The schedule explicitly prohibits companies from promoting cures or making claims related to diseases and disorders. These firms were found selling drugs claiming to cure diabetes, arthritis and kidney ailments.

According to FDA officials, the Ayurvedic medicine worth Rs 36,500 has been seized under Section 3 of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 from New Maruti Ayurved, Chinchwad, for making an objectionable claim on the label of Amruth Noni D Plus regarding the treatment of diabetes. Besides, Ayurvedic medicine Orthojoint Oil worth Rs 5,027 was seized from Amit Medico, Sadashiv Peth, for making an objectionable claim about the cure of arthritis on the label, they said.

Furthermore, 16 sachets of Ayurvedic medicine worth ₹5,000 were seized from Mahalaxmi Ayurvedic, Pune, for making an objectionable claim about the cure of kidney stones on the label.

Girish Hukare, joint commissioner, FDA(Drug), Pune division, said, in one case of diabetic medicines we have filed a case and investigations in the other two incidents are ongoing.

“The DMR Act 1954 is implemented through the FDA to prevent people from self-medicating for various diseases. Medicines taken without consulting a doctor for serious illnesses can have harmful effects,” he said.

Hukare, further, said, the FDA regularly checks the labelling of medicines available in the market. If misleading claims are found, action is taken against those people.

“Advertisements on television and newspapers are also checked, and if objectionable advertisements are found, the concerned manufacturer is given a notice to stop the advertisement, and further action is initiated by the respective drug authorities,” added Hukare.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’